glp-1 news october 21 2025 Who Gets the Shot? Access by State GLP-1-based therapy for obesity -

Studied for chronic inflammatory conditions, mast cell activation syndrome (MCAS), autoimmune support, and circadian rhythm dysregulation

Retatrutide has the unique dysesthesia concern that affects up to 20% of people at the highest dose

We aim to provide a reference process for the exploration and expression of new generation of psychrophilic enzymes

2025), which failed to find differences in drinking outcomes between NAC and placebo groups, in the present sub study, NAC-related decreases in frontal GABA levels were significantly associated with decreased drinks per drinking day, but not percent drinking days, across the treatment period